# Controlled Release Eczema Bandage (CREB)

> **NIH NIH R44** · CFD RESEARCH CORPORATION · 2024 · $656,274

## Abstract

Project Summary/Abstract:
 CFD Research Corporation has developed a novel microbiome-balancing wet wrap therapy for atopic
dermatitis based on a natural compound with unique physicochemical and pharmacological activities. The
compound has been found to have an interleukin-based immune modulatory effect that helps soothe the flare-
up of eczema, and it is highly selective to the pathogen Staphylococcus aureus while being gentle to the skin
microbiome, including beneficial bacteria such as Roseomonas mucosa and Corynebacterium
tuberculostearicum.
 The compound was incorporated into cellulose-based fabrics such as rayon and cotton to create a
controlled-release wet wrap/bandage which will be tested on mouse models of eczema. The technology has the
potential become a standard of care for treating eczema patients and decrease or eliminate the use of steroid
ointments in controlling atopic dermatitis in children and adult populations.

## Key facts

- **NIH application ID:** 10921604
- **Project number:** 2R44AT011486-02A1
- **Recipient organization:** CFD RESEARCH CORPORATION
- **Principal Investigator:** AJ Singhal
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $656,274
- **Award type:** 2
- **Project period:** 2021-08-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10921604

## Citation

> US National Institutes of Health, RePORTER application 10921604, Controlled Release Eczema Bandage (CREB) (2R44AT011486-02A1). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10921604. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*